Last updated: February 20, 2026
What is the current market landscape for Oxtellar XR?
Oxtellar XR, identified by NDC 00054-0470, is an extended-release formulation of oxcarbazepine used for seizure management. It is marketed by Supernus Pharmaceuticals and approved by the FDA since 2009.
Market Size and Growth
- The epilepsy treatment market in the U.S. was valued at approximately $4 billion in 2022.
- Oxtellar XR accounts for an estimated 4% of this market, translating to roughly $160 million annually.
- Compound annual growth rate (CAGR) for this sector stands at approximately 4.5%, with increased diagnosis rates and usage of extended-release formulations.
Key Competitors
| Drug Name |
Formulation |
Market Share (2022) |
Manufacturer |
| Oxtellar XR |
Extended-release (XR) |
4% |
Supernus Pharmaceuticals |
| Tegretol XR |
Extended-release |
17% |
Novartis |
| Vimpat |
Oral solution/tablets |
11% |
UCB |
| Kepra |
Extended-release |
10% |
UCB |
Patient and Prescriber Trends
- Prescriptions for extended-release oxcarbazepine grew by 6% YoY in 2022.
- The target demographic includes adult seizure patients, particularly those who benefit from stable plasma levels.
How is the pricing for NDC 00054-0470 structured?
Current Pricing
- The average wholesale price (AWP) for Oxtellar XR 600 mg is approximately $450 per 30-day supply.
- Insurance reimbursement rates vary; typical patient co-pays range from $25 to $75.
Historical Price Trends
- Prices have increased approximately 2% annually over the past five years.
- The price of equivalent formulations such as Tegretol XR remains around $400 for similar dosages, indicating a premium for Oxtellar XR’s dosing convenience.
Pricing Compared to Competitors
| Drug |
Average Wholesale Price |
Market Position |
| Oxtellar XR |
$450/30 days |
Premium, brand-name |
| Tegretol XR |
$400/30 days |
Mainstream generic |
| Vimpat |
$500/30 days |
Higher-end segment |
Reimbursement and Access
- Reimbursement rates depend on formulary status. Oxtellar XR is generally on Tier 2 or Tier 3 in commercial plans, influencing patient copays.
- Medicaid and Medicare Part D coverage is standard, with negotiated prices below AWP.
Price projections for 2023-2027
Factors Influencing Price Trends
- Patent exclusivity extensions or generic entry can alter pricing.
- Market penetration and prescriber adoption are likely to grow modestly, supporting stable pricing.
- Manufacturing costs for extended-release formulations may increase due to technological complexities.
Projected Price Trajectory
| Year |
Expected Average Wholesale Price (AWP) |
Notes |
| 2023 |
$460 - $470 |
Slight increase reflecting inflation |
| 2024 |
$470 - $490 |
Potential impact of generic competition delay |
| 2025 |
$480 - $500 |
Market stabilization |
| 2026 |
$485 - $510 |
Cost inflation pressures |
| 2027 |
$490 - $520 |
Possible market saturation, pricing pressure |
Volume and Revenue Outlook
- Prescriber adoption is expected to increase by 3-4% annually.
- Revenue growth hinges on market penetration rather than price hikes.
Key Takeaways
- Oxtellar XR holds a moderate share of extended-release antiseizure medication market, with steady but low growth.
- Pricing remains above $450 per 30-day supply, with margins influenced by formulary placement.
- Market competition and potential generic entry are factors to monitor for price stability.
- Revenue projections show slight increases, mainly driven by volume growth rather than price escalation.
Frequently Asked Questions
1. How does patent expiration impact Oxtellar XR pricing?
Patent expiration may lead to generic versions, which could reduce prices by 50% or more. Currently, Oxtellar XR’s patent is set to expire in 2024, with some formulations requiring legal challenges or extensions.
2. What is the likelihood of generic entry in the next two years?
Given patent status and market dynamics, generic versions could enter as early as late 2023 or 2024, potentially lowering brand-name prices.
3. How are insurance companies affecting access and pricing?
Insurance formulary preferences often favor generics; Oxtellar XR’s placement on Tier 2 or Tier 3 affects copay structures but generally maintains stable access.
4. What external factors could influence future prices?
Regulatory changes, manufacturing cost fluctuations, patent litigation, and market competition are primary factors influencing prices over the next five years.
5. How does Oxtellar XR compare in value to other treatments?
While priced higher than some formulations, Oxtellar XR offers extended-release benefits, potentially improving patient adherence and clinical outcomes.
References
[1] IQVIA. (2022). Prescription Drug Market Analysis.
[2] FDA. (2009). Approval Details for NDC 00054-0470.
[3] Supernus Pharmaceuticals. (2023). Oxtellar XR Prescribing Information.
[4] Medispan. (2022). Pricing Data for Antiseizure Drugs.
[5] Centers for Medicare & Medicaid Services. (2023). Drug Reimbursement Policies.
